代谢组学
流行病学
疾病
医学
生物信息学
生物
病理
作者
Harriett Fuller,Yiwen Zhu,Jayna Nicholas,Haley Chatelaine,Emily Drzymalla,Afrand K. Sarvestani,Sachelly Julián‐Serrano,Usman A. Tahir,Nasa Sinnott-Armstrong,Laura M. Raffield,Ali Rahnavard,Xinwei Hua,Katherine H. Shutta,Burcu F. Darst
标识
DOI:10.1038/s42255-023-00903-x
摘要
Metabolomic epidemiology is the high-throughput study of the relationship between metabolites and health-related traits. This emerging and rapidly growing field has improved our understanding of disease aetiology and contributed to advances in precision medicine. As the field continues to develop, metabolomic epidemiology could lead to the discovery of diagnostic biomarkers predictive of disease risk, aiding in earlier disease detection and better prognosis. In this Review, we discuss key advances facilitated by the field of metabolomic epidemiology for a range of conditions, including cardiometabolic diseases, cancer, Alzheimer's disease and COVID-19, with a focus on potential clinical utility. Core principles in metabolomic epidemiology, including study design, causal inference methods and multi-omic integration, are briefly discussed. Future directions required for clinical translation of metabolomic epidemiology findings are summarized, emphasizing public health implications. Further work is needed to establish which metabolites reproducibly improve clinical risk prediction in diverse populations and are causally related to disease progression. This Review article discusses how the emerging field of metabolomic epidemiology gives insight into the aetiology of various diseases and how these findings could be translated into clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI